RxDoctor Payments Data

Christina Miller, NP

Nurse Practitioner · Toledo, OHNPI 1427497890

Payments from drug & device makers

$3,440in general payments, 2019–2025

Across 170 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$405
  • Novartis$299
  • AstraZeneca$279
  • Johnson & Johnson$244
  • E.r. Squibb & Sons, L.L.C.$215
  • Alnylam Pharmaceuticals Inc.$209
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$3,40599%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,440 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$83,317
Medicare patients
573
Services billed
951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban235$203,294
XareltoRivaroxaban59$74,179
EntrestoSacubitril/Valsartan44$50,813
JardianceEmpagliflozin39$35,457
BrilintaTicagrelor27$18,940
FarxigaDapagliflozin Propanediol16$14,520
Repatha SureclickEvolocumab15$12,109
Metoprolol Succinate396$5,591
Dabigatran EtexilateDabigatran Etexilate Mesylate29$5,237
BystolicNebivolol Hcl12$2,155
Prasugrel Hcl22$1,891
Atorvastatin Calcium138$1,867
Nifedipine ErNifedipine49$1,731
Isosorbide Mononitrate ErIsosorbide Mononitrate114$1,474
Bumetanide53$1,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$405$203,294235 claims
Johnson & JohnsonXarelto$244$74,17959 claims
NovartisEntresto$299$50,81344 claims
Boehringer IngelheimJardiance$127$35,45739 claims
AstraZenecaBrilinta, Farxiga$279$33,46043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →